Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN)

被引：0
|
作者：
Glisson, Bonnie S.
Tseng, Jennifer
Marur, Shanthi
Shin, Dong M.
Murphy, Barbara A.
Cohen, Ezra E. W.
Thomas, Christopher Y.
Willey, Richard
Cosaert, Jan
William, William Nassib
Harun, Nusrat
Lee, J. Jack
Haddad, Robert I.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] MD Anderson Canc Ctr, Orlando, FL USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Vanderbilt Univ Sch Med, Deptartment Med, Nashville, TN USA
[6] Univ Chicago Med Ctr, Chicago, IL USA
[7] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[8] ImClone Syst LLC, Bridgewater, NJ USA
[9] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[10] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6030
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
    Seiwert, T. Y.
    Fayette, J.
    Cupissol, D.
    del Campo, J. M.
    Clement, P. M.
    Hitt, R.
    Degardin, M.
    Zhang, W.
    Blackman, A.
    Ehrnrooth, E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2014, 25 (09) : 1813 - 1820
  • [22] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients (pts) with cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Bauman, J. E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Varadarajan, Prakash
    Kotsakis, Athanasios Panayotis
    Martin, Daniel
    Gutkind, Jorge Silvio
    Gibson, Michael K.
    Argiris, Athanassios
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
    Argiris, A.
    Kotsakis, A. P.
    Hoang, T.
    Worden, F. P.
    Savvides, P.
    Gibson, M. K.
    Gyanchandani, R.
    Blumenschein, G. R., Jr.
    Chen, H. X.
    Grandis, J. R.
    Harari, P. M.
    Kies, M. S.
    Kim, S.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 220 - 225
  • [25] Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
    Bhatia, Aarti
    Mehra, Ranee
    Bauman, Jessica
    Khan, Saad A.
    Wei, Wei
    Neumeister, Veronique
    Sandoval-Schaefer, Teresa
    Alpaugh, R. Katherine
    Lango, Miriam
    Rimm, David L.
    Ridge, John A.
    Burtness, Barbara
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2025,
  • [26] Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and, neck (SCCHN) refractory to first-line platinum-based therapies.
    Vermorken, JB
    Bourhis, J
    Trigo, J
    Kies, M
    Leon, X
    Mueser, M
    Amellal, N
    Schueler, A
    Baselga, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 501S - 501S
  • [27] Randomized phase 2 trial of patritumab (P) or placebo (PBO) plus cetuximab (C) plus cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
    Harrington, Kevin J.
    Forster, Martin David
    Le Tourneau, Christophe
    Ariza, Jose
    Chen, Shuquan
    Greenberg, Jonathan
    Hirotani, Kenji
    Remenar, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study.
    Trigo, J
    Hitt, R
    Koralewski, P
    Diaz-Rubio, E
    Rolland, F
    Knecht, R
    Amellal, N
    Bessa, EH
    Baselga, J
    Vermorken, JB
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 488S - 488S
  • [29] Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Takeshita, Naohiro
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Wada, Akihisa
    Sato, Masanobu
    Tanaka, Hideki
    Tanaka, Nobukazu
    Onaga, Ryutaro
    Hoshi, Yuta
    Sakashita, Shingo
    Ishii, Genichiro
    Tahara, Makoto
    ORAL ONCOLOGY, 2023, 147
  • [30] The role of cetuximab maintenance after chemotherapy in patients with recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN): A retrospective analysis
    Wakasugi, T.
    Enokida, T.
    Nakanome, A.
    Yamazaki, T.
    Okano, S.
    Tahara, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 95 - 95
12345